Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS004 (Tifcemalimab) +/- JS001 (Toripalimab) in Head and Neck Cancer
NCT04929080Phase 2Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- May 2021
- Primary completion
- Mar 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tifcemalimab in head and neck squamous cell carcinoma (HNSCC), nasopharyngeal carcinoma (NPC), sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started May 2021; status: completed.
02
Drugs
tifcemalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04929080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04929080.